Literature DB >> 17512554

Nebivolol induces eNOS activation and NO-liberation in murine corpus cavernosum.

C Reidenbach1, R H G Schwinger, D Steinritz, K Kehe, H Thiermann, T Klotz, F Sommer, W Bloch, K Brixius.   

Abstract

Erectile function is critically dependent upon the activation of the endothelial nitric oxide synthase (eNOS) in the smooth muscle cells of penile corpus cavernosum tissue. Nebivolol is a beta(1)-selective beta-adrenoceptor blocker (beta-ARB) with additional vasodilating properties, which have been attributed to eNOS-activation. Our study investigated whether nebivolol is able to increase eNOS activity in erectile tissue. Murine penile tissue was incubated in an organ bath under control conditions and in the presence of nebivolol or metoprolol. Immunofluorescence staining was performed using specific antibodies against eNOS-activation or eNOS-serine 1177 phosphorylation. Corpus cavernosum smooth muscle tissue was identified using a smooth muscle actin antibody. In addition, slices of murine erectile tissue were incubated with diaminofluorescein (DAF), a specific fluorescence marker for NO-liberation. Under control conditions and after application of metoprolol, we observed a small eNOS-activation and serine 1177-phosphorylation in murine corpus cavernosum tissue. A significant increase in eNOS-activation and serine 1177-phosphorylation of eNOS was observed only in the presence of nebivolol (10 muM). These alterations of the eNOS protein induced after application of nebivolol were associated with a time-dependent increase in DAF fluorescence in murine erectile tissue. We conclude that beta-adrenoceptor blockers differentially influence erectile tissue. Since cardiovascular diseases are often associated with the development of erectile dysfunction, the nebivolol-induced eNOS-activation in corpus cavernosum may be beneficial when treating patients suffering from cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512554     DOI: 10.1016/j.lfs.2007.04.016

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Nebivolol does not protect against 5/6 ablation/infarction induced chronic kidney disease in rats - comparison with angiotensin II receptor blockade.

Authors:  Jennifer M Sasser; Natasha C Moningka; Tatsiana Tsarova; Chris Baylis
Journal:  Life Sci       Date:  2012-06-19       Impact factor: 5.037

2.  Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: a comparison with angiotensin II receptor blockade.

Authors:  Natasha C Moningka; Tatsiana Tsarova; Jennifer M Sasser; Chris Baylis
Journal:  Nephrol Dial Transplant       Date:  2011-08-19       Impact factor: 5.992

3.  Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.

Authors:  Otto Kamp; Marco Metra; Silvia Bugatti; Luca Bettari; Alessandra Dei Cas; Natalia Petrini; Livio Dei Cas
Journal:  Drugs       Date:  2010       Impact factor: 9.546

4.  Nebivolol compared with metoprolol for erectile function in males undergoing coronary artery bypass graft.

Authors:  Mustafa Aldemir; İbrahim Keleş; Mustafa Karalar; Evren Tecer; Fahri Adalı; Mehmet Bilgehan Pektaş; Ali İhsan Parlar; Osman Tansel Darçın
Journal:  Anatol J Cardiol       Date:  2015-02-11       Impact factor: 1.596

5.  Novel Tocolytic Strategy: Modulating Cx43 Activity by S-Nitrosation.

Authors:  Scott D Barnett; Hazik Asif; Mitchell Anderson; Iain L O Buxton
Journal:  J Pharmacol Exp Ther       Date:  2020-12-31       Impact factor: 4.030

Review 6.  Vascular system: role of nitric oxide in cardiovascular diseases.

Authors:  Ka Bian; Marie-Françoise Doursout; Ferid Murad
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-04       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.